NPS Pharmaceuticals to Report Third Quarter 2010 Financial Results

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter 2010 financial results on Tuesday, November 2, 2010 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial (866) 383-8108 and use passcode 39390430. International callers may dial (617) 597-5343, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website, http://www.npsp.com/events.

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 23473021 until midnight ET, November 16, 2010. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for parenteral nutrition dependent short bowel syndrome and is in preclinical development for pediatric indications and chemotherapy-induced gastrointestinal mucositis. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at http://www.npsp.com.



CONTACT:

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335

KEYWORDS:   United States  North America  Canada  New Jersey

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.